B Cell Lymphoma
News
CLL: Venetoclax combos top first-line chemoimmunotherapy
A triple-therapy combination yielded the best outcomes, but it should still be considered investigational.
News
CLL: Black patients die sooner than White patients
Researchers suspect that multiple factors – including biology – could be behind the racial disparity found in this large study.
News
B-cell cancers: Sparse insight into preventing infections
Doctors treating CLL and other B-cell cancers are blindsided by a lack of research into acquired hypogammaglobulinemia prophylactics.
News
CLL and surgery are more compatible than ever
As patients fare better with targeted therapy, physicians say they can tolerate more procedures.
News
CLL treatment: More infections among real-world patients
Among real-world blood cancer patients treated with three drugs, study finds higher infection rates than in clinical trials.
News
FDA approves first-in-class drug for follicular lymphoma
New treatment for relapsed/refractory follicular lymphoma, newly approved by the FDA, showed effectiveness in research presented at ASH 2022.
News
CAR T-cell therapy neurotoxicity linked to NfL elevations
Even prior to CAR T-cell therapy, patients developing related neurotoxic complications show elevated markers of neuronal injury.
News
Phase 3 data: Zanubrutinib bests standard CLL treatment
Results could spur FDA approval as frontline therapy.
News
Heed cardiac risk of BTKis for CLL
New consensus statement warns about cardiac risk of using BTKis, but a cardio-oncologist specialist questions its conclusions.
News
Drug shortages plague hematology, but preparedness helps
The plight of desperate patients is getting attention – and some remedies.